Academic Journal
NMDAR activation regulates the daily rhythms of sleep and mood
| العنوان: | NMDAR activation regulates the daily rhythms of sleep and mood |
|---|---|
| المؤلفون: | Burgdorf, Jeffrey S, Vitaterna, Martha H, Olker, Christopher J, Song, Eun Joo, Christian, Edward P, Sørensen, Laurits, Turek, Fred W, Madsen, Torsten M, Khan, M Amin, Kroes, Roger A, Moskal, Joseph R |
| المساهمون: | National Institutes of Health |
| المصدر: | Sleep ; volume 42, issue 10 ; ISSN 0161-8105 1550-9109 |
| بيانات النشر: | Oxford University Press (OUP) |
| سنة النشر: | 2019 |
| الوصف: | Study Objectives The present studies examine the effects of NMDAR activation by NYX-2925 diurnal rhythmicity of both sleep and wake as well as emotion. Methods Twenty-four-hour sleep EEG recordings were obtained in sleep-deprived and non-sleep-deprived rats. In addition, the day–night cycle of both activity and mood was measured using home cage ultrasonic-vocalization recordings. Results NYX-2925 significantly facilitated non-REM (NREM) sleep during the lights-on (sleep) period, and this effect persisted for 3 days following a single dose in sleep-deprived rats. Sleep-bout duration and REM latencies were increased without affecting total REM sleep, suggesting better sleep quality. In addition, delta power during wake was decreased, suggesting less drowsiness. NYX-2925 also rescued learning and memory deficits induced by sleep deprivation, measured using an NMDAR-dependent learning task. Additionally, NYX-2925 increased positive affect and decreased negative affect, primarily by facilitating the transitions from sleep to rough-and-tumble play and back to sleep. In contrast to NYX-2925, the NMDAR antagonist ketamine acutely (1–4 hours post-dosing) suppressed REM and non-REM sleep, increased delta power during wake, and blunted the amplitude of the sleep-wake activity rhythm. Discussion These data suggest that NYX-2925 could enhance behavioral plasticity via improved sleep quality as well as vigilance during wake. As such, the facilitation of sleep by NYX-2925 has the potential to both reduce symptom burden on neurological and psychiatric disorders as well as serve as a biomarker for drug effects through restoration of sleep architecture. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| DOI: | 10.1093/sleep/zsz135 |
| DOI: | 10.1093/sleep/zsz135/30023217/zsz135.pdf |
| الاتاحة: | http://dx.doi.org/10.1093/sleep/zsz135 http://academic.oup.com/sleep/advance-article-pdf/doi/10.1093/sleep/zsz135/30023217/zsz135.pdf http://academic.oup.com/sleep/article-pdf/42/10/zsz135/30122295/zsz135.pdf |
| Rights: | http://creativecommons.org/licenses/by-nc-nd/4.0/ |
| رقم الانضمام: | edsbas.1C4A439D |
| قاعدة البيانات: | BASE |
| DOI: | 10.1093/sleep/zsz135 |
|---|